{
    "nct_id": "NCT05681819",
    "title": "A Phase Ib, Randomized, Double-blind, Placebo-controlled, Multiple-ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacodynamics of Intravenous Administration of SHR-1707 In Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease",
    "status": "COMPLETED",
    "last_update_time": "2025-08-11",
    "description_brief": "Evaluate the Safety, Tolerability and Pharmacodynamics of Intravenous Administration of SHR-1707 In Patients with Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease.",
    "description_detailed": "N/A",
    "phase": [
        "PHASE1"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "OTHER",
    "results": null,
    "target_category": "disease-targeted biologic",
    "drug": [
        "SHR-1707"
    ],
    "placebo": [
        "placebo"
    ],
    "explanation_target": [
        "Reason: The investigational agent SHR-1707 is a humanized monoclonal antibody that binds amyloid\u2011\u03b2 (A\u03b2) \u2014 it\u2019s described in the literature and trial descriptions as an anti\u2011A\u03b2 mAb with activity against A\u03b2 monomers, protofibrils and fibrils, intended to reduce brain A\u03b2 deposition (i.e., targeting AD pathology). \ue200cite\ue202turn1search2\ue202turn1search6\ue201",
        "Act: Key trial details extracted \u2014 randomized, double\u2011blind, placebo\u2011controlled, multiple\u2011ascending dose IV study in patients with MCI due to Alzheimer\u2019s disease or mild AD (phase 1b / phase 2 style trials reported/registered). The intervention is SHR\u20111707 (intravenous) vs placebo; prior single\u2011dose phase 1 studies (2\u201360 mg/kg) showed acceptable safety/PK/PD supporting further development. \ue200cite\ue202turn1search2\ue202turn1search5\ue202turn1search1\ue201",
        "Web search results (supporting sources): 1) Alzheimer\u2019s & Dementia (Wiley) phase 1b trial description explicitly calls SHR\u20111707 a humanized anti\u2011A\u03b2 monoclonal antibody and describes the dose escalation study in MCI/mild AD. \ue200cite\ue202turn1search2\ue201 2) Full text / PMC and Alzheimer\u2019s Research & Therapy publication reporting single\u2011ascending\u2011dose phase 1 studies showing safety, PK/PD and PD effects on plasma A\u03b2 \u2014 supporting SHR\u20111707\u2019s mechanism and clinical development. \ue200cite\ue202turn1search6\ue202turn1search5\ue201 3) Trial registry/summary pages (NCT entries / trial listings) describing the randomized IV SHR\u20111707 vs placebo study in early AD patients. \ue200cite\ue202turn1search3\ue202turn1search0\ue201 4) Company (Jiangsu Hengrui) announcements reporting SHR\u20111707 as an anti\u2011A\u03b2 mAb and completion of early studies. \ue200cite\ue202turn1search7\ue201",
        "Reflect: Classification check \u2014 by the provided category definitions, a monoclonal antibody that directly targets Alzheimer\u2019s pathology (amyloid\u2011\u03b2) is a \"disease\u2011targeted biologic.\" There is no competing indication (e.g., purely symptomatic cognitive enhancer or neuropsychiatric symptomatic treatment), so the correct category is disease-targeted biologic. I found no ambiguity that would move this to another category. \ue200cite\ue202turn1search2\ue202turn1search6\ue201"
    ],
    "agent_type": "A) Amyloid beta",
    "explanation_agent": [
        "Reason: The investigational agent SHR-1707 is described in the literature and sponsor materials as a humanized monoclonal antibody that binds amyloid\u2011\u03b2 (A\u03b2) \u2014 with activity against A\u03b2 monomers, protofibrils and fibrils and intended to reduce brain A\u03b2 deposition, so the biological focus is directly on A\u03b2 pathology. \ue200cite\ue202turn0search0\ue202turn0search1\ue202turn0search2\ue201",
        "Act: Extracted trial/intervention details \u2014 randomized, double\u2011blind, placebo\u2011controlled multiple\u2011ascending\u2011dose IV Phase 1b study of SHR\u20111707 in patients with MCI due to AD or mild AD; earlier single\u2011dose Phase 1 studies showed safety and PK/PD supporting further development. These sources explicitly label SHR\u20111707 as an anti\u2011A\u03b2 monoclonal antibody. \ue200cite\ue202turn0search0\ue202turn0search5\ue202turn0search4\ue201",
        "Reflect: The CADRO classification that best fits an intervention that directly targets amyloid\u2011\u03b2 pathology is 'A) Amyloid beta.' There is no indication the intervention targets tau, inflammation, synaptic function, or is multi\u2011target \u2014 the evidence consistently describes a single disease\u2011targeted biologic directed at A\u03b2. Therefore the correct CADRO assignment is A) Amyloid beta. \ue200cite\ue202turn0search0\ue202turn0search1\ue201",
        "Web search results (supporting sources cited above): 1) Phase 1b trial description in Alzheimer's & Dementia (Wiley) describing SHR\u20111707 as a humanized anti\u2011A\u03b2 antibody and the randomized dose\u2011escalation study. \ue200cite\ue202turn0search0\ue201 2) Company (Jiangsu Hengrui) announcement describing SHR\u20111707 as an anti\u2011\u03b2\u2011amyloid monoclonal antibody and reporting early study enrollment/completion. \ue200cite\ue202turn0search1\ue201 3) ALZFORUM therapeutic entry summarizing SHR\u20111707 as an anti\u2011A\u03b2 IgG1 mAb (amyloid\u2011related target). \ue200cite\ue202turn0search2\ue201 4) Full\u2011text publication reporting Phase 1 single\u2011dose studies (safety, PK/PD) supportive of development. \ue200cite\ue202turn0search5\ue201 5) Alzheimer's & Dementia abstract on SHR\u20111707 single\u2011dose studies summarizing safety and PD (dose range 2\u201360 mg/kg). \ue200cite\ue202turn0search4\ue201"
    ]
}